NASDAQ:PCRXPacira Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pacira Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $55.33 -0.25 (-0.45 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$54.19Now: $55.33▼$56.6850-Day Range$42.53MA: $47.52▼$57.8052-Week Range$27.46Now: $55.33▼$59.93Volume742,101 shsAverage Volume705,448 shsMarket Capitalization$2.33 billionP/E RatioN/ADividend YieldN/ABeta1.31 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is based in Parsippany, New Jersey.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingPacira Biosciences has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 10 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $59.14, Pacira Biosciences has a potential upside of 6.9% from its current price of $55.33.Amount of Analyst CoveragePacira Biosciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.9 Community Rank Outperform VotesPacira Biosciences has received 741 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPacira Biosciences has received 554 “underperform” votes. (Add your “underperform” vote.)Community SentimentPacira Biosciences has received 57.22% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Pacira Biosciences and other stocks. Vote “Outperform” if you believe PCRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPacira Biosciences does not currently pay a dividend.Dividend GrowthPacira Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacira Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,337,870.00 in company stock.Percentage Held by InsidersOnly 6.20% of the stock of Pacira Biosciences is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Pacira Biosciences are expected to grow by 187.13% in the coming year, from $1.01 to $2.90 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira Biosciences is -2,765.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira Biosciences is -2,765.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioPacira Biosciences has a PEG Ratio of 2.74. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioPacira Biosciences has a P/B Ratio of 6.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.42 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PCRX Previous Symbol CUSIP69512710 CIK1396814 Webwww.pacira.com Phone973-254-3560Debt Debt-to-Equity Ratio0.94 Current Ratio5.37 Quick Ratio4.63Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio54.78 P/E Growth2.74 Sales & Book Value Annual Sales$421.03 million Price / Sales5.54 Cash Flow$1.65 per share Price / Cash Flow33.47 Book Value$8.51 per share Price / Book6.50Profitability EPS (Most Recent Fiscal Year)$0.86 Net Income$-11,020,000.00 Net Margins-0.02% Return on Equity13.89% Return on Assets6.06%Miscellaneous Employees518 Outstanding Shares42,121,000Market Cap$2.33 billion Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:PCRX Rates by TradingView Receive PCRX News and Ratings via Email Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Pacira Biosciences (NASDAQ:PCRX) Frequently Asked Questions How has Pacira Biosciences' stock been impacted by COVID-19 (Coronavirus)? Pacira Biosciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PCRX stock has increased by 57.2% and is now trading at $55.33. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Pacira Biosciences? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacira Biosciences. When is Pacira Biosciences' next earnings date? Pacira Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Pacira Biosciences. How were Pacira Biosciences' earnings last quarter? Pacira Biosciences Inc (NASDAQ:PCRX) issued its quarterly earnings data on Thursday, May, 7th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.30 by $0.23. The company had revenue of $105.68 million for the quarter, compared to analysts' expectations of $101.64 million. Pacira Biosciences had a negative net margin of 0.02% and a positive return on equity of 13.89%. The firm's revenue for the quarter was up 15.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.22 EPS. View Pacira Biosciences' earnings history. What guidance has Pacira Biosciences issued on next quarter's earnings? Pacira Biosciences updated its second quarter 2020 After-Hours earnings guidance on Monday, July, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $75.5-75.5 million, compared to the consensus revenue estimate of $57.81 million. What price target have analysts set for PCRX? 15 brokers have issued 12 month price objectives for Pacira Biosciences' shares. Their forecasts range from $41.00 to $85.00. On average, they anticipate Pacira Biosciences' stock price to reach $59.14 in the next twelve months. This suggests a possible upside of 6.9% from the stock's current price. View analysts' price targets for Pacira Biosciences. Has Pacira Biosciences been receiving favorable news coverage? Media headlines about PCRX stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pacira Biosciences earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Pacira Biosciences. Who are some of Pacira Biosciences' key competitors? Some companies that are related to Pacira Biosciences include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors. What other stocks do shareholders of Pacira Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Celgene (CELG), Clovis Oncology (CLVS), NVIDIA (NVDA), Bausch Health Companies (BHC), Exelixis (EXEL), Micron Technology (MU), Incyte (INCY) and Neurocrine Biosciences (NBIX). Who are Pacira Biosciences' key executives? Pacira Biosciences' management team includes the following people: Mr. David M. Stack, Chairman & CEO (Age 69)Mr. Charles A. Reinhart III, CPA, M.B.A., Chief Financial Officer (Age 58)Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 45)Dr. Richard Scranton M.D., MPH, Chief Medical Officer (Age 52)Mr. Dennis McLoughlin, Chief Commercial Officer (Age 53) What is Pacira Biosciences' stock symbol? Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX." Who are Pacira Biosciences' major shareholders? Pacira Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include MERIAN GLOBAL INVESTORS UK Ltd (0.33%), State of Alaska Department of Revenue (0.09%), Toth Financial Advisory Corp (0.03%) and Envestnet Asset Management Inc. (0.01%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings, Richard Scranton and Roy Winston. View institutional ownership trends for Pacira Biosciences. Which major investors are buying Pacira Biosciences stock? PCRX stock was purchased by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Toth Financial Advisory Corp, Envestnet Asset Management Inc., and State of Alaska Department of Revenue. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace, Mark A Kronenfeld, and Roy Winston. View insider buying and selling activity for Pacira Biosciences. How do I buy shares of Pacira Biosciences? Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Pacira Biosciences' stock price today? One share of PCRX stock can currently be purchased for approximately $55.33. How big of a company is Pacira Biosciences? Pacira Biosciences has a market capitalization of $2.33 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe. What is Pacira Biosciences' official website? The official website for Pacira Biosciences is www.pacira.com. How can I contact Pacira Biosciences? Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected] This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
